US EditionHIV-Prevention Drug to Be Available for US$40 a Year From 2027
The generic drug lenacapavir will cost $40 annually, reducing HIV transmission by over 99.9% in low- and middle-income countries from 2027, partners said.
- September 24th, 2025: The Gates Foundation and Clinton Health Access Initiative partnered with Hetero and Dr. Reddy's to produce generic lenacapavir priced at $40 annually from 2027 across 120 countries.
- Facing limited access, Yeztugo by Gilead Sciences costs about $80 million in the U.S., prompting licensing deals and the foundation's $80 million investment to accelerate generics.
- Perez Casas said `The product is going to be at the beginning manufactured in India` and clinical data show lenacapavir reduces HIV risk by more than 99.9%.
- Gilead and the Global Fund will supply reduced-price branded doses this year while generics ramp up production, aiming to deliver first units to at least one African country by year-end.
- Some experts say global funding efforts, including Gates' pledge, aim to increase PrEP access from 18%, potentially transforming HIV prevention and control.
15 Articles
15 Articles
This drug, injected only twice a year, has better results than other treatments currently used in the prevention of HIV transmission. But so far, its very high price could make it inaccessible to many people at risk.
HIV-Prevention Drug To Be Available For Rs 3,500 A Year From 2027
Generic versions of a groundbreaking injectable HIV-prevention drug should be available for $40 or Rs 3,548 a year in more than 100 countries from 2027, Unitaid and the Gates Foundation said Wednesday.
Indian drugmakers Dr Reddy’s, Hetero to sell generic HIV prevention drug for US$40 a year
MUMBAI, Sept 24 — Indian drugmakers Dr Reddy’s Laboratories and Hetero Labs said today that they will sell generic versions of a new and highly effective HIV prevention drug for roughly US$40 (RM168.40) per year beginning in 2027.Lenacapavir, developed by Gilead Sciences and approved earlier this year for HIV prevention under the brand name Yeztugo, is a twice-yearly injection that was nearly 100 per cent effective at preventing HIV in large tri…
Coverage Details
Bias Distribution
- 57% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
